Teva Pharmaceutical Industries Ltd (TEVA) 50.85 $TEVA
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE(R) Patent Due to the Potential for the Company to Recover Patent Infringement Damages
Business Wire - 1 hr 44 mins ago
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that while the Chief Justice of the United States found that Teva had demonstrated "a fair prospect of success on the merits" in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"
, he denied the Company's application to stay the Federal Circuit's decision due to the potential for the Company to recover patent infringement damages. The '808 patent expires on September 1, 2015 and claims a process for manufacturing the active ingredient of Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE(R) (glatiramer acetate injection) 20mg/mL. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for COPAXONE(R).
Court declines to block drug ruling in patent case
By SAM HANANEL - AP - Fri Apr 18, 3:39PM CDT
WASHINGTON (AP) — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month.
Philadelphia Parkinson's Disease CommUNITY Rallied At Rocky Statue Launching New Public Awareness Campaign From The Parkinson's Unity Walk Organization And Teva
PR Newswire - Thu Apr 17, 9:15AM CDT
Teva Pharmaceuticals, makers of AZILECT® (rasagiline tablets) a once-daily treatment for Parkinson's disease (PD), and the Parkinson's Unity Walk (PUW) announces the launch of a public awareness campaign, "CommUNITY: Carrying the PD Torch," to support Parkinson's disease (PD) patients during Parkinson's Disease Awareness Month in April. The campaign aims to empower patients to set their goals and work to achieve them by uniting the community and encouraging patients in their PD journey.
Teva Settles Patent Litigation with Pfizer on Celebrex(R)
Business Wire - Thu Apr 17, 7:37AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex(R) (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex(R) were $2.2 billion in the U.S. according to IMS data as of December, 2013.
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 15, 4:31PM CDT
In just a few months Isis Pharmaceuticals has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year. But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking...
Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).
Teva Announces Launch of Generic Lunesta(R) Tablets in the United States
Business Wire - Tue Apr 15, 11:25AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta(R) (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States.
Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price...
This Is the Toughest Part of Investing
Chuck Saletta, The Motley Fool - Motley Fool - Mon Apr 14, 8:14AM CDT
This past week was a tough one for the overall market and the real-money Inflation-Protected Income Growth portfolio . The iPIG portfolio lost more than $1,150 in market price since last week's update , as the S&P 500 dropped about 2.6% in that...
Regulatory Approvals, Earnings and Conference Call Schedules, and Stock Price Updates - Analyst Notes on Teva, Allergan, Boston Scientific, Covidien and Thermo Fisher
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Boston Scientific Corporation (NYSE: BSX), Covidien Plc (NYSE: COV) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1089-100free.
Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018
M2 - Mon Apr 14, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone, whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Recombinant peptide market is divided into Calcitonin and Glucagon. Of all the segments, the key traction segment that is estimated to grow at a faster rate of 25% by 2018 is the recombinant glycosylated proteins segment. This growth can mainly be attributed to investments by drug manufacturers to develop biosimilar versions of monoclonal antibodies (more than 50 biosimilars of monoclonal antibodies are in the pipeline), the introduction of the new biosimilar drug Ovaleap' (follitropin) to treat infertility, and the growing demand for erythropoietin and monoclonal antibodies to treat cancer. Monoclonal antibody is one of the lucrative markets for drug manufacturers, for x future investment to develop MAb at a large scale and is also estimated to be the fastest growing market at an estimated CAGR of 41.9% from 2013 to 2018. About eight biologic MAb drugs are expected become off-patent products from 2013 to 2018. The drugs that are expected to lose their patent protections are Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis. The three most targeted products for biosimilars are Rituximab, Infliximab, and Adalimumab due to their high worldwide sales and approvals for multiple indications. Various key industry players of the generics market have started working on the manufacturing and clinical trial activities of MAbs. At present, approximately 50 biosimilar MAbs are in the pipeline. Bioexpress Therapeutic (Switzerland) has 16 biosimilar candidates of MAbs that are in the pipeline. The other players that have invested in the production of MAbs are GeneTechno Science (Japan), Celltrion (South Korea), Zydus-Cadila (India), Biocon (India), and Samsung Biologics (South Korea). Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Analysis - Global Biosimilars Market, By Product - Global Biosimilar Market, By Application - Global Biosimilars Service Market - Geographic Analysis - Competitive Landscape - Company Profiles - Actavis, Inc. - Amgen, Inc. - Biocon Ltd. - Celltrion, Inc. - Cipla Ltd. - Dr. Reddy'S Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Hospira, Inc. - Lg Life Sciences Ltd. - Merck Kgaa - Mylan, Inc. - Ranbaxy Laboratories Ltd. - Roche Holding Ltd. - Sandoz International Gmbh - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd. - Wockhardt Ltd. Visit http://www.researchandmarkets.com/research/8r...iosimilars
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE(R) Patent Due to the Potential for the Company to Recover Patent Infringement Damages
Business Wire - 1 hr 44 mins ago
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that while the Chief Justice of the United States found that Teva had demonstrated "a fair prospect of success on the merits" in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"
, he denied the Company's application to stay the Federal Circuit's decision due to the potential for the Company to recover patent infringement damages. The '808 patent expires on September 1, 2015 and claims a process for manufacturing the active ingredient of Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE(R) (glatiramer acetate injection) 20mg/mL. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for COPAXONE(R). Court declines to block drug ruling in patent case
By SAM HANANEL - AP - Fri Apr 18, 3:39PM CDT
WASHINGTON (AP) — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month.
Philadelphia Parkinson's Disease CommUNITY Rallied At Rocky Statue Launching New Public Awareness Campaign From The Parkinson's Unity Walk Organization And Teva
PR Newswire - Thu Apr 17, 9:15AM CDT
Teva Pharmaceuticals, makers of AZILECT® (rasagiline tablets) a once-daily treatment for Parkinson's disease (PD), and the Parkinson's Unity Walk (PUW) announces the launch of a public awareness campaign, "CommUNITY: Carrying the PD Torch," to support Parkinson's disease (PD) patients during Parkinson's Disease Awareness Month in April. The campaign aims to empower patients to set their goals and work to achieve them by uniting the community and encouraging patients in their PD journey.
Teva Settles Patent Litigation with Pfizer on Celebrex(R)
Business Wire - Thu Apr 17, 7:37AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex(R) (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex(R) were $2.2 billion in the U.S. according to IMS data as of December, 2013.
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
Business Wire - Wed Apr 16, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.
Global Testicular Cancer Drugs Market 2014-2018 with Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating
M2 - Wed Apr 16, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7567b6/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer. The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin). Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs. Key vendors dominating this space include: - Bristol-Myers Squibb Co - Hospira Inc. - Teva Pharmaceutical Industries Ltd. - ZIOPHARM Oncology Inc. Other vendors mentioned in the report are: - Baxter International Inc. - Fresenius Kabi Pharmaceuticals Holding Inc. - Mylan Pharmaceutical Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Testicular Cancer by Type - Testicular Cancer Disease by Stages - Treatment Options - Clinical Trial Snapshot - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/75...testicular
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 15, 4:31PM CDT
In just a few months Isis Pharmaceuticals has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year. But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking...
Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).
Teva Announces Launch of Generic Lunesta(R) Tablets in the United States
Business Wire - Tue Apr 15, 11:25AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta(R) (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States.
Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price...
This Is the Toughest Part of Investing
Chuck Saletta, The Motley Fool - Motley Fool - Mon Apr 14, 8:14AM CDT
This past week was a tough one for the overall market and the real-money Inflation-Protected Income Growth portfolio . The iPIG portfolio lost more than $1,150 in market price since last week's update , as the S&P 500 dropped about 2.6% in that...
Regulatory Approvals, Earnings and Conference Call Schedules, and Stock Price Updates - Analyst Notes on Teva, Allergan, Boston Scientific, Covidien and Thermo Fisher
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Boston Scientific Corporation (NYSE: BSX), Covidien Plc (NYSE: COV) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1089-100free.
Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018
M2 - Mon Apr 14, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone, whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Recombinant peptide market is divided into Calcitonin and Glucagon. Of all the segments, the key traction segment that is estimated to grow at a faster rate of 25% by 2018 is the recombinant glycosylated proteins segment. This growth can mainly be attributed to investments by drug manufacturers to develop biosimilar versions of monoclonal antibodies (more than 50 biosimilars of monoclonal antibodies are in the pipeline), the introduction of the new biosimilar drug Ovaleap' (follitropin) to treat infertility, and the growing demand for erythropoietin and monoclonal antibodies to treat cancer. Monoclonal antibody is one of the lucrative markets for drug manufacturers, for x future investment to develop MAb at a large scale and is also estimated to be the fastest growing market at an estimated CAGR of 41.9% from 2013 to 2018. About eight biologic MAb drugs are expected become off-patent products from 2013 to 2018. The drugs that are expected to lose their patent protections are Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis. The three most targeted products for biosimilars are Rituximab, Infliximab, and Adalimumab due to their high worldwide sales and approvals for multiple indications. Various key industry players of the generics market have started working on the manufacturing and clinical trial activities of MAbs. At present, approximately 50 biosimilar MAbs are in the pipeline. Bioexpress Therapeutic (Switzerland) has 16 biosimilar candidates of MAbs that are in the pipeline. The other players that have invested in the production of MAbs are GeneTechno Science (Japan), Celltrion (South Korea), Zydus-Cadila (India), Biocon (India), and Samsung Biologics (South Korea). Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Analysis - Global Biosimilars Market, By Product - Global Biosimilar Market, By Application - Global Biosimilars Service Market - Geographic Analysis - Competitive Landscape - Company Profiles - Actavis, Inc. - Amgen, Inc. - Biocon Ltd. - Celltrion, Inc. - Cipla Ltd. - Dr. Reddy'S Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Hospira, Inc. - Lg Life Sciences Ltd. - Merck Kgaa - Mylan, Inc. - Ranbaxy Laboratories Ltd. - Roche Holding Ltd. - Sandoz International Gmbh - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd. - Wockhardt Ltd. Visit http://www.researchandmarkets.com/research/8r...iosimilars
